Pediatric Formulation Of Malaria Drug Shown To Prevent Disease Relapse In Children, Study Shows; Developers Hope To Receive Regulatory Approval

Devex: Study finds malaria drug can also prevent relapse in children
“After a new study found a pediatric formulation of a malaria drug is effective in preventing relapse of the disease in children months after treatment, developers are hopeful this latest evidence would lead to regulatory approval of the drug. The formulation provides a simpler treatment option for children infected with the Plasmodium vivax parasite that causes malaria. … MMV and GSK plan to use this latest evidence for regulatory submissions in Australia, and subsequently other malaria-endemic countries…” (Ravelo, 12/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.